Cita APA (7a ed.)
B, D., RB, D., SE, K., S, J., G, B., U, d. F., . . . Beevers, G. (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet, 359(9311), 995-1004.
Cita Chicago Style (17a ed.)
B, Dahlöf, et al. "Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol." Lancet 359, no. 9311 (2002): 995-1004.
Cita MLA (9a ed.)
B, Dahlöf, et al. "Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol." Lancet, vol. 359, no. 9311, 2002, pp. 995-1004.
Precaución: Estas citas no son 100% exactas.